Core Insights - The article highlights the successful completion of a Series B financing round by Ruifuda Medical, led by a fund managed by CICC Capital, with participation from the Lianyungang Economic and Technological Development Zone Industrial Fund [1][3] - The funds raised will be primarily allocated to technology research and development, market expansion both domestically and internationally, production capacity upgrades, and team building [1] Company Overview - Ruifuda Medical, established in 2018 and headquartered in Lianyungang, Jiangsu, focuses on the research and development of domestic reproductive assistance reagents and consumables [3] - The founding team has over 20 years of industry experience and has been involved in the entire process from laboratory products to standardized industrialization, creating a complete system that integrates research, production, and operations [3] Product Line - The company specializes in consumables and reagent product development for assisted reproductive technology (ART), covering key stages such as low-temperature storage, embryo culture, and in vitro fertilization (IVF) [3] - Key products include: - Vitrification freezing solution set: Used for embryo cryopreservation [3] - Vitrification thawing solution set: Used for embryo thawing [5] Technological Advancements - Ruifuda Medical has invested continuously in technology development, having filed for 6 invention patents [7] - The core product, the closed vitrification carrier rod, was officially approved for market release in March 2025, addressing critical issues of "rapid cooling" and "closed contamination prevention" in vitrification [7][9] - The company's oocyte optimization solution is the world's first professional and efficient oocyte cytoplasm maturation optimization solution, which enhances oocyte quality and increases the rates of high-quality embryo formation and blastocyst development [7] - The self-developed vitrification freezing and thawing solution sets received FDA registration approval in April 2025 [7]

Core Viewpoint - Ruifuda Medical has recently completed a Series B financing round of several tens of millions, led by a fund managed by CICC Capital, with participation from the Lianyungang Economic and Technological Development Zone Industrial Fund. The funds will primarily be used for technology research and development, market expansion, capacity upgrades, and team building [1] Group 1: Company Overview - Ruifuda Medical, established in 2018, focuses on the research and development of consumables and reagents in the assisted reproductive field. The founder, Fu Yang, has over 20 years of experience in the industry and has been involved in the entire process from laboratory product development to industrialization [1] - The company’s product pipeline covers key areas in in vitro fertilization (IVF), including low-temperature storage, embryo culture, and in vitro fertilization processes [1] Group 2: Product Development - In March of this year, Ruifuda Medical's core patented product, a closed vitrification rod for assisted reproductive embryo freezing technology, was officially approved for market launch. This technology reduces freezing damage and extends storage periods by creating a non-crystalline glass state at ultra-low temperatures [2] - The closed vitrification rod addresses two critical issues in the freezing process: rapid cooling and contamination prevention. It utilizes a unique liquid refrigerant design to achieve cooling rates comparable to open rods while effectively isolating samples from direct contact with liquid nitrogen [2] Group 3: Market Expansion and Recognition - As product development matures, Ruifuda Medical is gradually advancing its market promotion. In April, the company’s self-developed vitrification and thawing liquid set received FDA registration approval in the United States. The company aims to accelerate domestic market entry and capacity expansion while significantly expanding into international markets [4] - To date, Ruifuda Medical has filed six invention patents and successfully obtained recognition as a national high-tech enterprise as of March 2025 [4] Group 4: Investor and Company Perspectives - CICC Capital expressed that Ruifuda Medical demonstrates strong R&D capabilities and efficient industrialization in the assisted reproduction sector, positioning it as a leader in domestic medical devices. The investment aims to support the company in building stronger technological barriers and broader market prospects [5] - Ruifuda Medical views this Series B financing as a critical milestone in its development, marking an important step towards higher standards in domestic assisted reproductive devices. The company plans to continue driving technological innovation, enhancing quality control, and improving service capabilities for global application of its core products [5]